Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AR Antivirals for treatment of HIV infections, combinations
J05AR08 Emtricitabine, tenofovir disoproxil and rilpivirine
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine <US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Combinations
Emtricitabine/ Rilpivirine/ Tenofovir Disoproxil Fumarate
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HIV reverse transcriptase inhibitor
D10571 Rilpivirine hydrochloride, tenofovir disoproxil fumarate and emtricitabine <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10571
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10571